Trial Profile
A longitudinal, retrospective real-life study exploring the clinical outcome of natalizumab and fingolimod.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 13 Apr 2018 New trial record